Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SURPASS-3 in recurrent MAGE-A4-positive ovarian cancer
2024-512138-13-00Phase 2Completed
- Sponsor
- US WorldMeds
- Start
- Sep 2023
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, TCR-Engineered T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies, Gene Therapies
- Countries
- 5
01
Overview
Phase 2, randomised, open-label trial in ovarian cancer, primary peritoneal cancer (PPC) and fallopian tube cancer (PFTC) comparing ADP-A2M4CD8 monotherapy with ADP-A2M4CD8 plus Opdivo (2 arms). Primary endpoint: Objective response. Started Sep 2023; status: completed.
02
Drugs
ADP adoptive cell therapynivolumab
03
Conditions
ovarian cancerprimary peritoneal cancer (PPC)fallopian tube cancer (PFTC)
Beyond the preview
Go deeper on 2024-512138-13-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-512138-13-00.